Alumis Inc. Common Stock

NASDAQ:ALMS

Biotechnology

Healthcare
$4.40 +0.91%

+$0.21 today

Market cap
$568.87M
Beta
-0.54
P/E (TTM)
-12.2
EPS (TTM)
-$1.90
52W Low $2.76High $30.60

Volume 2.01M

Average 1.31M

ALMS Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Alumis Inc. Common StockNASDAQ: ALMS

Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026

Income tax expense remains negative

Q2 FY2026 income tax expense was -$1.76M, compared with -$8.56M a year earlier. Trailing-twelve-month income tax expense was -$1.76M.

Context

  • Income tax expense amounted to 35.6% of revenue in FY2025.
  • Income tax expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near -$1.76M or moves back toward the trailing-twelve-month quarterly average of -$439.25K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$1.76M— QoQ
Last fiscal yearDec 2025
-$8.56M— YoY
LTMJun 2026
-$1.76M+79.5% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+79.5%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
(8.56M) USD
Year-over-year change
—

Income Tax Expense vs competitors

How ALMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +79.5% is the 5th highest of 7, against a peer median of +100.3%.
  • Income tax expense amounts to 23.7% of revenue for ALMS, versus a peer median of 41.9%.
ALMS Competitors
Income Tax Expense for ALMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$169K USD+47.0%+80.6%286.4%
ANABAnaptysBio, Inc.LTM Mar 2026$160K USD+240.4%+89.8%0.1%
IFRXInflaRx N.V.LTM Mar 2026€12.28K EUR+135.4%—41.9%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€4K EUR+100.6%——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$0 USD———
TLSATiziana Life Sciences LtdFY2025$0 USD+100.0%——
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$0 USD———
ALMSAlumis Inc. Common StockLTM Jun 2026-$1.76M USD+79.5%—23.7%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026-$242.26M USD-25708.8%—80.8%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ALMS) —+100.3%+85.2%41.9%

Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00024.05M
Cost of Revenue250K03.15M3.5M
Gross Profit(250K)0(3.15M)20.55M
Gross Margin———85.5%
Research & Development101.05M137.68M265.55M386M
Selling, General & Admin12.55M20.5M35.2M91.86M
Operating Expenses113.6M158.17M297.6M447.76M
Depreciation & Amortization250K1.28M3.15M3.5M
EBITDA(111.68M)(153.71M)(291.08M)(248.39M)
EBITDA Margin———-1032.8%
Operating Income(113.85M)(158.17M)(300.75M)(427.2M)
Operating Margin———-1776.3%
Interest Income1.99M3.37M12.02M14.18M
Interest Expense0000
Other Income / Expenses1.92M3.18M6.52M175.32M
Income Before Tax(111.93M)(154.99M)(294.23M)(251.89M)
Pre-Tax Margin———-1047.3%
Income Tax Expense000(8.56M)
Net Income(111.93M)(154.99M)(294.23M)(243.33M)
Net Margin———-1011.7%
EPS (Basic)(14.93)(2.99)(10.38)(2.32)
EPS (Diluted)(14.93)(2.99)(10.38)(2.32)
Weighted Avg Shares7.5M51.84M28.34M850.3M
Weighted Avg Shares (Diluted)7.5M51.84M28.34M850.3M

Alumis Inc. Common Stock

NASDAQ:ALMS

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.